Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02179853 · ClinicalTrials.gov registry record · Phase 1
Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02179853 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 22 participants.
The verdict
NCT02179853, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery abnormalities that may lead to complications later in life, including heart attack. Although the investigators can identify children with KD that have these coronary artery abnormalities, there is no approved additional treatment to decrease coronary artery inflammation and arrest or prevent damage to the coronary arteries. Anakinra, a therapy that blocks the high levels of interleukin 1 (IL1) that lead to inflammation during acute KD, has been shown in the KD mouse model to prevent the development of coronary artery damage. Therefore, the investigators propose to study the safety and activity of anakinra in infants and children \< 2 years old with coronary artery abnormalities from KD.
Interventions
- DRUG Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-11 |
| Est. Completion | 2022-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02179853
The ClinicalTrials.gov registry entry for NCT02179853 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anakinra is the first listed.
NCT02179853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02179853 about?
NCT02179853 is a clinical study titled "Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease". Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the developed world. Despite available treatment, 25% of children in San Diego County appropriately treated for KD develop coronary artery abnormalities that may lead to complications later in life, including heart a...
What is the current status of trial NCT02179853?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2014-11. Estimated completion is 2022-12.
What interventions are being tested in trial NCT02179853?
The interventions under investigation include: Anakinra (DRUG).
Who is sponsoring clinical trial NCT02179853?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.